Advertisement

Topics

UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen

01:01 EDT 20 Apr 2018 | FinanzNachrichten

BRUSSELS, April 20, 2018 /PRNewswire/ -- Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures...

Original Article: UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen

NEXT ARTICLE

More From BioPortfolio on "UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen"

Advertisement
Quick Search
Advertisement
Advertisement